Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
29
XHS Quote, Financials, Valuation and Earnings
Last price:
$90.80
Seasonality move
:
3.31%
Day range:
$90.37 - $90.82
52-week range:
$85.93 - $100.30
Dividend yield:
0.37%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
859
Avg. volume:
2.5K
1-year change:
1.27%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XHS
SPDR S&P Health Care Services ETF
|
$90.82 | -- | -- | -- | $0.08 | 0.37% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$60.56 | -- | -- | -- | $0.00 | 0% | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
$12.35 | -- | -- | -- | $0.00 | 0% | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
$27.21 | -- | -- | -- | $0.13 | 1.65% | -- |
|
SURI
Simplify Propel Opportunities ETF
|
$15.86 | -- | -- | -- | $0.68 | 20.74% | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$43.41 | -- | -- | -- | $0.15 | 1.56% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XHS
SPDR S&P Health Care Services ETF
|
-- | 1.413 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 1.316 | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | 2.118 | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | 1.073 | -- | -- |
|
SURI
Simplify Propel Opportunities ETF
|
-- | 1.741 | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 1.021 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
SPDR S&P Health Care Services ETF vs. Competitors
-
Which has Higher Returns XHS or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XHSSPDR S&P Health Care Services ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About XHS or BBP?
SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings XHSSPDR S&P Health Care Services ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is XHS or BBP More Risky?
SPDR S&P Health Care Services ETF has a beta of 1.019, which suggesting that the stock is 1.88% more volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.32%.
-
Which is a Better Dividend Stock XHS or BBP?
SPDR S&P Health Care Services ETF has a quarterly dividend of $0.08 per share corresponding to a yield of 0.37%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XHS or BBP?
SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XHSSPDR S&P Health Care Services ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns XHS or CNCR?
Range Cancer Therapeutics ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XHSSPDR S&P Health Care Services ETF-- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- -
What do Analysts Say About XHS or CNCR?
SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than Range Cancer Therapeutics ETF.
Company Buy Ratings Hold Ratings Sell Ratings XHSSPDR S&P Health Care Services ETF0 0 0 CNCRRange Cancer Therapeutics ETF0 0 0 -
Is XHS or CNCR More Risky?
SPDR S&P Health Care Services ETF has a beta of 1.019, which suggesting that the stock is 1.88% more volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.71%.
-
Which is a Better Dividend Stock XHS or CNCR?
SPDR S&P Health Care Services ETF has a quarterly dividend of $0.08 per share corresponding to a yield of 0.37%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XHS or CNCR?
SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XHSSPDR S&P Health Care Services ETF-- -- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- --
-
Which has Higher Returns XHS or FTXH?
First Trust Nasdaq Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat First Trust Nasdaq Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XHSSPDR S&P Health Care Services ETF-- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- -
What do Analysts Say About XHS or FTXH?
SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than First Trust Nasdaq Pharmaceuticals ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than First Trust Nasdaq Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings XHSSPDR S&P Health Care Services ETF0 0 0 FTXHFirst Trust Nasdaq Pharmaceuticals ETF0 0 0 -
Is XHS or FTXH More Risky?
SPDR S&P Health Care Services ETF has a beta of 1.019, which suggesting that the stock is 1.88% more volatile than S&P 500. In comparison First Trust Nasdaq Pharmaceuticals ETF has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.157%.
-
Which is a Better Dividend Stock XHS or FTXH?
SPDR S&P Health Care Services ETF has a quarterly dividend of $0.08 per share corresponding to a yield of 0.37%. First Trust Nasdaq Pharmaceuticals ETF offers a yield of 1.65% to investors and pays a quarterly dividend of $0.13 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. First Trust Nasdaq Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XHS or FTXH?
SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than First Trust Nasdaq Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while First Trust Nasdaq Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for First Trust Nasdaq Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XHSSPDR S&P Health Care Services ETF-- -- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns XHS or SURI?
Simplify Propel Opportunities ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat Simplify Propel Opportunities ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XHSSPDR S&P Health Care Services ETF-- -- -- SURISimplify Propel Opportunities ETF-- -- -- -
What do Analysts Say About XHS or SURI?
SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Simplify Propel Opportunities ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than Simplify Propel Opportunities ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than Simplify Propel Opportunities ETF.
Company Buy Ratings Hold Ratings Sell Ratings XHSSPDR S&P Health Care Services ETF0 0 0 SURISimplify Propel Opportunities ETF0 0 0 -
Is XHS or SURI More Risky?
SPDR S&P Health Care Services ETF has a beta of 1.019, which suggesting that the stock is 1.88% more volatile than S&P 500. In comparison Simplify Propel Opportunities ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock XHS or SURI?
SPDR S&P Health Care Services ETF has a quarterly dividend of $0.08 per share corresponding to a yield of 0.37%. Simplify Propel Opportunities ETF offers a yield of 20.74% to investors and pays a quarterly dividend of $0.68 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. Simplify Propel Opportunities ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XHS or SURI?
SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than Simplify Propel Opportunities ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than Simplify Propel Opportunities ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while Simplify Propel Opportunities ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for Simplify Propel Opportunities ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XHSSPDR S&P Health Care Services ETF-- -- -- -- SURISimplify Propel Opportunities ETF-- -- -- --
-
Which has Higher Returns XHS or XPH?
SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XHSSPDR S&P Health Care Services ETF-- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About XHS or XPH?
SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings XHSSPDR S&P Health Care Services ETF0 0 0 XPHSPDR S&P Pharmaceuticals ETF0 0 0 -
Is XHS or XPH More Risky?
SPDR S&P Health Care Services ETF has a beta of 1.019, which suggesting that the stock is 1.88% more volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.759, suggesting its less volatile than the S&P 500 by 24.059%.
-
Which is a Better Dividend Stock XHS or XPH?
SPDR S&P Health Care Services ETF has a quarterly dividend of $0.08 per share corresponding to a yield of 0.37%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.56% to investors and pays a quarterly dividend of $0.15 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XHS or XPH?
SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XHSSPDR S&P Health Care Services ETF-- -- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
